Agios Pharmaceuticals opened lower at $32.56, compared with its previous close of $32.82. In the last trading session, the stock traded between $31.56 and $32.76. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Agios Pharmaceuticals is now worth
$ 74.16
Resulting in a loss of
$ 25.84 (25.84%)
Note: Past profits do not guarantee future returns.
Rating from 6 Analysts
Today's Change
$-1.08 (-3.28%)
Day High
$32.76
Day Low
$31.56
Day Open
$32.56
Prev Close
$32.82
Volume
3,50,057
1W Return
1.21%
1M Return
2.97%
3M Return
-2.83%
6M Return
13.40%
1Y Return
-27.63%
Market Cap ($ Mn)
1,898
PE Ratio
-
PB Ratio
1.94
PEG Ratio
-
ROE
-30.11%
ROCE
-33.53%
EPS (TTM)
$-1.09
1 Week
1.21%
1 Month
2.97%
3 Months
-2.83%
6 Months
13.40%
9 Months
14.55%
Truist Securities maintains Buy on Agios, cuts price target to $35
Truist Securities maintains a Buy rating on Agios Pharmaceuticals. Price target lowered from $37 to $35 by analyst Gregory Renza. The rating change reflects an updated valuation outlook.
6 days agoAgios Pharmaceuticals Q3FY26 results: Revenue up 4x; HC Wainwright raises PT
Agios Pharmaceuticals reported Q3FY26 revenue of $55.4 million, up 329% YoY. Net loss narrowed to $65 million from $103.4 million in the prior year period. HC Wainwright maintained Buy rating and raised price target to $62 from $55. Mitapivat U.S. net revenue reached $48.7 million driven by thalassemia launch.
6 days agoHematologists seek broader SCD arsenal beyond gene therapy, survey shows
Mitapivat interest rose threefold to 24%, making it the top desired pipeline therapy. 70% of hematologists rate unmet need in sickle cell disease as high. 51% of patients are not optimally managed with current treatments. New therapies require 46% VOC reduction and 1.9 g/dL hemoglobin increase to succeed. Etavopivat prescribing interest jumped to 57% following Phase III results.
2mo agoCitigroup raises Agios Pharmaceuticals price target to $52
Citigroup maintains a Buy rating on Agios Pharmaceuticals and raises its price target from $46 to $52. Analyst Samantha Semenkow leads the recommendation, highlighting the stock's potential for further appreciation.
3mo agoPomerantz probes Agios Pharmaceuticals over drug trial failure
Agios Pharmaceuticals faces a securities fraud investigation by Pomerantz LLP after announcing the cessation of its tebapivat drug development on July 21, 2026, following unsuccessful Phase 2 clinical trials for sickle cell disease.
3mo agoAgios Pharmaceuticals Q2 Results: Revenue surges 259% YoY
Agios Pharmaceuticals delivered strong Q2 2026 results with revenue jumping to $44.7 million, fueled by the US launch of AQVESME. The net loss improved to $100.7 million. Key pipeline updates include FDA Priority Review for mitapivat in sickle cell disease and the licensing of cevidoplenib, though tebapivat development was halted.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Agios Pharmaceuticals is now worth
$ 74.16
Resulting in a loss of
$ 25.84 (25.84%)
Note: Past profits do not guarantee future returns.
